FDA panel supports approval of Boehringer's olodaterol for COPD

An FDA advisory panel endorsed the approval of Boehringer Ingelheim's olodaterol as a once-daily bronchodilator treatment for chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Boehringer plans to market the drug in a soft mist inhaler under the name Striverdi Respimat.

View Full Article in:

Bloomberg Businessweek · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC